Financial Data and Key Metrics Changes - For Q1 2025, revenue from sales of MPEFA was reported at $1.1 million, compared to $1.1 million for Q1 2024 [25] - Research and development expenses increased to $15.3 million from $14.4 million year-over-year, reflecting expenses associated with late-stage development programs [25] - Selling, general, and administrative expenses decreased significantly to $11.6 million from $32.1 million, primarily due to strategic repositioning efforts [25] - The net loss for Q1 2025 was $25.3 million or $0.07 per share, compared to a net loss of $48.4 million or $0.20 per share for the same period in 2024 [25] - Cash and short-term investments at the end of Q1 2025 were $194.8 million, down from $238 million at the end of 2024 [26] Business Line Data and Key Metrics Changes - The company announced an exclusive license agreement with Novo Nordisk for LX9851, which includes potential milestone payments of up to $1 billion and tiered royalties on future net sales [5][6] - The Phase 2b study of pilavapitan showed a well-tolerated dose with clear evidence of effect, paving the way for Phase 3 studies [7][9] - Enrollment in the global pivotal Sonata HCM study of sotagliflozin is on track, with expectations for all Phase III sites to be operational by Q3 2025 [13][18] Market Data and Key Metrics Changes - Approximately 9 million people in the U.S. are currently affected by diabetic peripheral neuropathic pain (DPNP), with projections to grow to 13 million by 2035 [10] - In the U.S., there are over 1 million people with hypertrophic cardiomyopathy (HCM), with a significant portion having non-obstructive HCM [14] Company Strategy and Development Direction - The company is focused on advancing its R&D programs and has restructured its cost base to support this pivot [7][8] - The partnership with Novo Nordisk is seen as a validation of the science behind LX9851 and aims to maximize its market potential [6][20] - The company is committed to advancing pilavapitan for DPNP and sotagliflozin for HCM, with plans for further regulatory engagement and data presentations [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of pilavapitan to be the first novel oral non-opioid DPNP medication in over two decades, highlighting the significant unmet need in this market [9][11] - The company anticipates stable U.S. MPEFA revenues despite limited promotional activity and expects lower cash usage in subsequent quarters [26][27] - Management is optimistic about the upcoming catalysts and the potential for new partnerships to enhance the value of its pipeline [28][30] Other Important Information - The company has revised its operating expense guidance for 2025, expecting total operating expenses between $135 million and $145 million [27] - The partnership with Beatrice for sotagliflozin includes a $25 million upfront payment and potential milestone payments of up to $200 million [21] Q&A Session Summary Question: Can you discuss the intended trial designs for the pain program? - The plan is to run two parallel trials with similar designs, one U.S.-only and the other worldwide, with approximately 300-350 patients per arm [34] Question: How are the IND enabling studies for LX9851 progressing? - The IND enabling studies are on track for completion this year, with a strong collaborative relationship with Novo Nordisk [43] Question: Is the end of Phase II meeting a gating factor for strategic discussions? - It is not seen as a gating factor; discussions with strategic partners will continue concurrently [52] Question: What additional data will be presented at medical meetings? - Additional detail on secondary analyses related to pain quality and functionality will be shared, along with pharmacokinetic data [55] Question: How is the Sonata trial designed to create a homogeneous population? - The trial focuses on symptomatic disease, which is reflective of diastolic dysfunction, and is powered for both obstructive and non-obstructive HCM [59][66]

Core Viewpoint - Theravance Biopharma reported a wider-than-expected adjusted net loss for Q1 2025, indicating ongoing financial challenges despite a year-over-year revenue increase driven by collaboration revenues from Viatris [1][2]. Financial Performance - The adjusted net loss for Q1 2025 was 17 cents per share, compared to a loss of 11 cents estimated by Zacks Consensus, and a loss of 9 cents in the same quarter last year [1]. - Total revenues for the first quarter were $15.4 million, missing the Zacks Consensus Estimate of $16 million, but representing a 6.2% increase year-over-year due to higher collaboration revenues from Viatris [2]. - The reported loss, including share-based compensation and other expenses, was 27 cents per share, compared to a loss of 24 cents in the prior year [2]. Collaboration and Revenue Sources - Revenues were entirely derived from Viatris' collaboration related to Yupelri (revefenacin) sales, which is used for chronic obstructive pulmonary disease treatment [4]. - Viatris recorded $58.3 million in U.S. net sales of Yupelri for Q1 2025, reflecting a 6% year-over-year increase [6]. - Theravance receives 35% of the profits from Yupelri sales, while Viatris retains 65% [5]. Expenses and Financial Guidance - Research and development expenses (excluding share-based compensation) were $10.4 million, up 40.5% from the previous year, while selling, general, and administrative expenses increased by 13.2% to $14.6 million [10]. - Theravance reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses between $32 million and $38 million, and SG&A expenses between $50 million and $60 million [11]. Pipeline Developments - Theravance is developing ampreloxetine, a norepinephrine reuptake inhibitor for treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy [12]. - The phase III CYPRESS study for ampreloxetine is expected to complete patient enrollment by late summer, with top-line data anticipated six months post-enrollment [13].

YUPELRI Performance and Potential - YUPELRI net sales for Q1 2025 reached $58.3 million, a 6% increase compared to Q1 2024[10, 24] - Hospital doses of YUPELRI increased by 48% in Q1 2025 compared to Q1 2024[10, 20] - Theravance Biopharma receives 35% of US profits from YUPELRI sales due to a co-promotion agreement with Viatris[9, 11, 16, 23, 58] - A $25 million milestone is achievable if US net sales of YUPELRI exceed $250 million, requiring a 5% growth from 2024[24, 57] - Viatris submitted an NDA in China for YUPELRI in June 2024, with a potential $45 million milestone and 14-20% tiered royalties for Theravance Biopharma[24, 57] TRELEGY Milestones and Royalties - 2024 TRELEGY net sales reached $854 million, a 14% year-over-year increase, positioning the company to trigger a $50 million milestone in 2025[10, 27] - Theravance Biopharma could receive up to $150 million in TRELEGY sales milestones in 2025 and 2026[9, 27, 57] - To trigger the first $25 million milestone in 2025, Royalty Pharma needs to receive $260 million or more in royalty payments from GSK, equivalent to $3063 billion in TRELEGY global net sales[9] - Royalties from TRELEGY net sales, ranging from 5.5% to 8.5%, will return to Theravance Biopharma starting July 1, 2029 (ex-US) and January 1, 2031 (US), extending through the mid-2030s[32, 34, 57, 58] Financial Overview - Theravance Biopharma's cash and cash equivalents totaled $130.9 million at the end of Q1 2025, including a $50 million TRELEGY milestone payment received in February 2025, with no debt[10, 50, 57] - Non-GAAP net loss for Q1 2025 was $8.6 million, compared to $4.5 million for Q1 2024[45, 50] - VIATRIS collaboration revenue was $15.4 million in Q1 2025, compared to $14.5 million in Q1 2024[45, 50]

Financial Data and Key Metrics Changes - YUPELRI net sales increased by 6% to just over $58 million, driven by demand growth and favorable pricing [2][4] - Collaboration revenue reported at $15.4 million, up 6% year over year, with YUPELRI brand level cash profitability growing faster than collaboration revenue [16][18] - Operating expenses, excluding share-based compensation, increased to $25 million, primarily due to R&D and SG&A expenses [17][18] - The company ended the quarter with $131 million in cash and no debt, reflecting a strong financial position [18][22] Business Line Data and Key Metrics Changes - Hospital doses of YUPELRI increased by 48% year on year, achieving record high volume with approximately 316,000 units pulled through the hospital channel [2][6] - The performance of YUPELRI in the hospital setting is a key strategic differentiator, contributing significantly to overall brand growth [5][6] - TRELEGY reported global net sales of $854 million, up 14% year over year, positioning the company to achieve a $50 million milestone in 2025 [4][10] Market Data and Key Metrics Changes - Market research indicates significant future potential for YUPELRI, with additional demand growth expected [7] - The company is focused on transitioning hospital patients to community maintenance care, which is critical for long-term growth [6][8] Company Strategy and Development Direction - The company aims to deliver high-quality results in the Sypris trial, with a focus on enrolling the right patients and optimizing study factors [3][12] - YUPELRI is positioned as a foundational and highly profitable asset, with plans to achieve a $25 million near-term milestone and extended IP protection through 2039 [8][9] - The company is preparing for an expedited NDA submission for ampreloxetine, with ongoing engagement with the MSA community [12][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving higher-end milestones for TRELEGY, with consensus estimates for 2025 and 2026 increasing by approximately $100 million [10][11] - The company does not anticipate material impacts from potential tariff measures and remains focused on its value drivers [19][21] - Management highlighted the importance of the transition of care for hospital patients to ensure they receive ongoing treatment [28][30] Other Important Information - The company is actively engaging with payers regarding ampreloxetine and its potential role in treating nOH [33][34] - Five out of eight Paragraph IV filers have been settled regarding YUPELRI, with three litigants remaining [38] Q&A Session Summary Question: Status update on ampreloxetine manufacturing and IP - The IP for ampreloxetine is currently in Ireland, with API manufacturing outside the U.S. in Taiwan, allowing flexibility for future adjustments [26] Question: Efforts to increase hospital prescriptions to filled chronic prescriptions - The company is focused on ensuring patients receive support through fulfillment programs and follow-up care after leaving the hospital [27][30] Question: Feedback from payers on ampreloxetine - The company has started engaging with payers to educate them on the disease burden and the potential role of ampreloxetine [33][34] Question: Update on Paragraph IV filers for YUPELRI - Settlements have been reached with five of the eight filers, with three outstanding litigants [38]

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.59%. A quarter ago, it was expected that this medical research equipment and services provider would post earnings of $2.50 per share when it actually produced earnings of $2.66, delivering a surprise ...

Core Viewpoint - Heron Therapeutics has entered into a settlement agreement with Mylan Pharmaceuticals to resolve patent litigations, allowing Mylan to market generic versions of CINVANTI® and APONVIE® starting June 1, 2032, or earlier under certain conditions [1][2]. Group 1: Settlement Agreement Details - The settlement resolves ongoing patent litigations initiated by Heron in September 2023 and January 2024 against Mylan's applications for generic versions of CINVANTI® and APONVIE® [2]. - Mylan will receive a license under the Heron Patents to market the generic drugs in the U.S. [1][2]. Group 2: Company Background - Heron Therapeutics is a commercial-stage biotechnology company focused on developing therapeutic innovations to improve patient care, particularly in acute care and oncology [3]. - The company utilizes advanced science and patented technologies to create and commercialize a portfolio of products aimed at enhancing the standard of care [3].

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids, aiming to improve patient experience through rapid delivery and reduced treatment burden [3] - Halozyme has impacted one million patient lives through post-marketing use of ten commercialized products across more than 100 global markets [3] Product and Technology - Halozyme has licensed its ENHANZE® technology to major pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and AbbVie, among others [3] - The company also develops and commercializes drug-device combination products using advanced auto-injector technologies, which offer advantages such as improved convenience, reliability, and patient comfort [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing product development programs with partners like Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 4:20 PM PT / 7:20 PM ET [1] - A live audio webcast of the presentation will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [2]

Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative solutions [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of drugs and fluids [3] - Halozyme has impacted over one million patients through its technology, which is used in ten commercialized products across more than 100 global markets [3] Product Development - Halozyme develops, manufactures, and commercializes drug-device combination products, leveraging advanced auto-injector technologies to enhance convenience, reliability, and patient comfort [4] - The company has two proprietary commercial products: Hylenex® and XYOSTED®, along with partnered products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Financial Results - Halozyme will release its first quarter 2025 financial and operating results on May 6, 2025, after the market closes [1] - A conference call to discuss these results will take place on the same day at 1:30 p.m. PT/4:30 p.m. ET, with live access available through pre-registration [1][2]

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Viatris, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/viatris-inc. Investors have until June 3, 2025, to ask the Court to be appointed to lead the cas ...

SAN DIEGO, April 21, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Viatris Inc. (NASDAQ: VTRS) securities between August 8, 2024 and February 26, 2025. Viatris is a global healthcare company that supplies medicines to patients across more than 165 countries and territories via its 26 manufacturing and packaging sites worldwide.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a ...